Gout Therapeutic Market (Drug Type - Colchicine, Antihyperuricemic Agents (Urate-Lowering Drugs), Non-steroidal Anti-inflammatory Drugs (NSAIDs), Corticosteroids, Biologic Response Modifiers (Biologics); Distribution Channel - Hospital Pharmacy, Retail Pharmacy, Online Pharmacy) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2019 - 2030

Description

The global gout therapeutic market is driven by high prevalence and rapid increase in incidence of gout arthritis across the globe. The global gout therapeutics market was valued at US$ 1874 Mn in 2018 and is projected to reach US$ 3820 Mn by 2027, expanding at a CAGR of 8.3% from 2019 to 2027.

High growth rate of the gout therapeutics market is attributed because of following factors

Increase in drug pipeline

Easy availability,

Rise in the demand for biologics for treatment of gout across the globe. 

Gout is a type of inflammatory arthritis caused by small crystals of a chemical called uric acid that form in the joints. If uric acid levels in the blood remain elevated, thin rod-like crystals can form and deposit in the joints, which can lead to severe pain, tenderness, stiffness, swelling, and joint damage. 

Gout has both active and inactive periods. Active periods of gout are known as ‘attacks’ and can vary in severity and length. Diagnosis of gout is confirmed by synovial fluid analysis. Incidence of gout has been rising consistently over the last few years.

According to Nationwide Emergency Department Sample (NEDS), total number of ED visits per year among patients with a primary diagnosis of acute gout increased 26.8% between 2006 and 2014; from 168,580 to 213,780. 

Traditional therapies are witnessing a shift toward biologics. Rise in demand for effective treatment and new therapeutics launches are projected to propel the global gout therapeutics market during the forecast period. Efforts are being taken in various countries to spread awareness about chronic diseases and role of biologics in treating gout among the general population. 

The global gout therapeutic market has been segmented based on drug type, distribution channel, and region. In terms of drug type, the gout therapeutics market has been classified into NSAIDS, colchicine, corticosteroids, antihyperuricemic agents (urate-lowering drugs), and biologics. The antihyperuricemic agents (urate-lowering drugs) segment dominated the gout therapeutics market in 2018. 

The segment is projected to expand at a high CAGR from 2019 to 2027. Biologics have witnessed rapid adoption and are replacing NSAIDS and corticosteroids owing to better results. Hence, the biologics segment is anticipated to expand at a rapid pace and is likely to gain gout therapeutics market share during the forecast period. 

Antihyperuricemic agents (urate-lowering drugs) are usually prescribed as the first line of treatment. Moreover, adoption and success of Target-2-Treat (T2T) strategy using a combination of biologic and conventional synthetic urate-lowering drugs for the treatment of severe gout disease are key factors fueling biologic and antihyperuricemic agents segments. 

Based on distribution channel, the global gout therapeutics market has been categorized into hospital pharmacy, retail pharmacy, and online pharmacy. The retail pharmacy segment accounted for major share of the global market in 2018, followed by hospital pharmacy and online pharmacy segments. 

global gout therapeutics market 2

Increase in the number of multinational hospitals and preference to take injectable biologic drug products at hospitals is estimated to drive the hospital pharmacy segment.

Increasing number of hospitals in developing countries, such as India China, Singapore, and Malaysia is further fueling the segment. 

In terms of region, the global gout therapeutics market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America accounted for significant share of the global market in 2018, followed by Europe.

global gout therapeutics market

Well-established health care facilities, favorable reimbursement policies, and early adoption of therapeutics for the treatment of gout contributed to the high gout therapeutics market share held by North America. Europe is projected to be the second-most attractive market for gout therapeutics from 2019 to 2027.

The gout therapeutics market in the Europe is anticipated to expand at a high CAGR during the forecast period, due to high prevalence and increase in incidence of gout and high per capita health care expenditure in the region. 

The global gout therapeutics market is consolidated, with several companies accounting for majority market share. Key players operating in the global market include Takeda Pharmaceutical Company Limited, Teijin Pharma Limited., Novartis AG, Mylan N.V., and Horizon Pharma plc. These players exhibit significant geographic outreach, with presence in multiple gout therapeutics segments. 

Manufacturers are adopting acquisition & collaboration and new product development strategies to tap the unmet needs of a large proportion of patient pool. Other prominent players in the global gout therapeutics market include Teva Pharmaceutical Industries Ltd., Hikma Pharmaceuticals PLC, Iroko Pharmaceuticals, LLC, and MERCK & CO., Inc.

The global gout therapeutics market has been segmented as follows:

Drug Type

  • Colchicine
  • Antihyperuricemic Agents (Urate-Lowering Drugs)
  • Non-steroidal Anti-inflammatory Drugs (NSAIDs)
  • Corticosteroids
  • Biologic Response Modifiers (Biologics)

Distribution Channel

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy

Region

  • North America
  • U.S.
  • Canada
  • Europe
  • U.K.
  • Germany
  • France
  • Italy
  • Spain
  • Rest of Europe
  • Asia Pacific
  • China
  • India
  • Japan
  • Australia & New Zealand
  • Rest of Asia Pacific
  • Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
  • Middle East & Africa
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

TABLE OF CONTENT

1.Preface
      1.1. Market Definition and Scope
      1.2. Market Segmentation
      1.3. Key Research Objectives
      1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary : Global Gout Therapeutics Market 

4. Market Overview
      4.1. Introduction
              4.1.1. Component Definition
              4.1.2. Industry Evolution / Developments
      4.2.  Overview
      4.3. Market Dynamics
              4.3.1. Drivers
              4.3.2. Restraints
              4.3.3. Opportunities
      4.4. Global Gout Therapeutics Market Analysis and Forecast, 2017–2030
              4.4.1. Market Revenue Projections (US$ Mn)
      4.5. Porter’s Five Force Analysis

5. Market Outlook
      5.1.Epidemiological Overview of Gout Arthritis
      5.2.Pipeline Analysis

6. Global Gout Therapeutics Market Analysis and Forecast, by Component 
      6.1. Introduction & Definition
      6.2. Key Findings / Developments
      6.3. Global Gout Therapeutics Market Value Forecast, by Drug Type, 2017–2030
              6.3.1. Colchicine
              6.3.2. Antihyperuricemic agents (Urate-Lowering Drugs) 
              6.3.3. Non-steroidal Anti-inflammatory Drugs (NSAIDs)
              6.3.4. Corticosteroids
              6.3.5. Biologic Response Modifiers (Biologics)
      6.4. Global Gout Therapeutics Market Attractiveness, by Drug Type  

7 Global Gout Therapeutics Market Analysis and Forecast, by Distribution Channel 
      7.1. Introduction & Definition
      7.2. Key Findings / Developments
      7.3. Global Gout Therapeutics Market Value Forecast, by Distribution Channel, 2017–2030
              7.3.1. Hospital Pharmacy
              7.3.2. Retail Pharmacy
              7.3.3. Online Pharmacy
      7.4. Global Gout Therapeutics Market Attractiveness, by Distribution Channel 

8. Global Gout Therapeutics Market Analysis and Forecast, by Region
      8.1. Key Findings
      8.2. Global Gout Therapeutics Market Value Forecast, by Region
              8.2.1. North America 
              8.2.2. Europe 
              8.2.3. Asia Pacific 
              8.2.4. Latin America 
              8.2.5. Middle East & Africa 
      8.3. Global Gout Therapeutics Market Attractiveness, by Country/Region

9. North America Gout Therapeutics Market Analysis and Forecast
      9.1. Introduction
              9.1.1. Key Findings
      9.2. North America Gout Therapeutics Market Value Forecast, by Drug Type, 2017–2030
              9.2.1. Colchicine
              9.2.2. Antihyperuricemic agents (Urate-Lowering Drugs) 
              9.2.3. Non-steroidal Anti-inflammatory Drugs (NSAIDs)
              9.2.4. Corticosteroids
              9.2.5. Biologic Response Modifiers (Biologics)
      9.3. North America Gout Therapeutics Market Value Forecast, by Distribution Channel, 2017–2030
              9.3.1. Hospital Pharmacy
              9.3.2. Retail Pharmacy
              9.3.3. Online Pharmacy
      9.4. North America Gout Therapeutics Market Value Forecast, by Country, 2017–2030
              9.4.1. U.S.
              9.4.2. Canada
      9.5. North America Gout Therapeutics Market Attractiveness Analysis 
              9.5.1. By Drug Type
              9.5.2. By Distribution Channel 
              9.5.3. By Country

10. Europe Gout Therapeutics Market Analysis and Forecast
      10.1. Introduction
              10.1.1. Key Findings
      10.2. Europe Gout Therapeutics Market Value Forecast, by Drug Type, 2017–2030
              10.2.1. Colchicine
              10.2.2. Antihyperuricemic agents (Urate-Lowering Drugs) 
              10.2.3. Non-steroidal Anti-inflammatory Drugs (NSAIDs)
              10.2.4. Corticosteroids
              10.2.5. Biologic Response Modifiers (Biologics)
      10.3. Europe Gout Therapeutics Market Value Forecast, by Distribution Channel, 2017–2030
              10.3.1. Hospital Pharmacy
              10.3.2. Retail Pharmacy
              10.3.3. Online Pharmacy
      10.4. Europe Gout Therapeutics Market Value Forecast, by Country/Sub-region, 2017–2030
              10.4.1. Germany
              10.4.2. U.K.
              10.4.3. France
              10.4.4. Spain
              10.4.5. Italy
              10.4.6. Rest of Europe
      10.5. Europe Gout Therapeutics Market Attractiveness Analysis 
              10.5.1. By Drug Type 
              10.5.2. By Distribution Channel 
              10.5.3. By Country/Sub-region

11. Asia Pacific Gout Therapeutics Market Analysis and Forecast
      11.1.Introduction
              11.1.1. Key Findings
      11.2. Asia Pacific Gout Therapeutics Market Value Forecast, by Drug Type, 2017–2030
              11.2.1. Colchicine
              11.2.2. Antihyperuricemic agents (Urate-Lowering Drugs) 
              11.2.3. Non-steroidal Anti-inflammatory Drugs (NSAIDs)
              11.2.4. Corticosteroids
              11.2.5. Biologic Response Modifiers (Biologics)
      11.3. Asia Pacific Gout Therapeutics Market Value Forecast, by Distribution Channel, 2017–2030
              11.3.1. Hospital Pharmacy
              11.3.2. Retail Pharmacy
              11.3.3. Online Pharmacy
      11.4. Asia Pacific Gout Therapeutics Market Value Forecast, by Country/Sub-region, 2017–2030
              11.4.1. China
              11.4.2. Japan
              11.4.3. India
              11.4.4. Australia & New Zealand
              11.4.5. Rest of Asia Pacific
      11.5. Asia Pacific Gout Therapeutics Market Attractiveness Analysis 
              11.5.1. By Drug Type 
              11.5.2. By Distribution Channel 
              11.5.3. By Country/Sub-region

12. Latin America Gout Therapeutics Market Analysis and Forecast
      12.1.Introduction
              12.1.1. Key Findings
      12.2. Latin America Gout Therapeutics Market Value Forecast, by Drug Type, 2017–2030
              12.2.1. Colchicine
              12.2.2. Antihyperuricemic agents (Urate-Lowering Drugs) 
              12.2.3. Non-steroidal Anti-inflammatory Drugs (NSAIDs)
              12.2.4. Corticosteroids
              12.2.5. Biologic Response Modifiers (Biologics)
      12.3. Latin America Gout Therapeutics Market Value Forecast, by Distribution Channel, 2017–2030
              12.3.1. Hospital Pharmacy
              12.3.2. Retail Pharmacy
              12.3.3. Online Pharmacy
      12.4. Latin America Gout Therapeutics Market Value Forecast, by Country/Sub-region, 2017–2030
              12.4.1. Brazil
              12.4.2. Mexico
              12.4.3. Rest of Latin America
      12.5. Latin America Gout Therapeutics Market Attractiveness Analysis 
              12.5.1. By Drug Type
              12.5.2. By Distribution Channel 
              12.5.3. By Country/Sub-region

13. Middle East & Africa Gout Therapeutics Market Analysis and Forecast
      13.1.Introduction
              13.1.1. Key Findings
      13.2. Middle East & Africa Gout Therapeutics Market Value Forecast, by Drug Type, 2017–2030
              13.2.1. Colchicine
              13.2.2. Antihyperuricemic agents (Urate-Lowering Drugs) 
              13.2.3. Non-steroidal Anti-inflammatory Drugs (NSAIDs)
              13.2.4. Corticosteroids
              13.2.5. Biologic Response Modifiers (Biologics)
      13.3. Middle East & Africa Gout Therapeutics Market Value Forecast, by Distribution Channel, 2017–2030
              13.3.1. Hospital Pharmacy
              13.3.2. Retail Pharmacy
              13.3.3. Online Pharmacy
      13.4. Middle East & Africa Gout Therapeutics Market Value Forecast, by Country/Sub-region, 2017–2030
              13.4.1. GCC Countries
              13.4.2. South Africa
              13.4.3. Rest of Middle East & Africa
      13.5.Market Attractiveness Analysis 
              13.5.1. By Drug Type
              13.5.2. By Distribution Channel 
              13.5.3. By Country/Sub-region

14. Competition Landscape
      14.1. Company Profiles
              14.1.1. Takeda Pharmaceutical Company Limited
                         14.1.1.1. Company Overview (HQ, Business Segments, Employee Strengths)
                         14.1.1.2 Product Portfolio
                         14.1.1.3. SWOT Analysis 
                         14.1.1.4. Strategic Overview
                         14.1.1.5. Financial Overview
              14.1.2. Teijin Pharma Limited
                         14.1.2.1. Company Overview (HQ, Business Segments, Employee Strengths)
                         14.1.2.2 Product Portfolio
                         14.1.2.3. SWOT Analysis 
                         14.1.2.4. Strategic Overview
              14.1.3. Novartis AG
                         14.1.3.1. Company Overview (HQ, Business Segments, Employee Strengths)
                         14.1.3.2 Product Portfolio
                         14.1.3.3. SWOT Analysis 
                         14.1.3.4. Strategic Overview
                         14.1.3.5. Financial Overview
              14.1.4. Mylan N.V.
                         14.1.4.1. Company Overview (HQ, Business Segments, Employee Strengths)
                         14.1.4.2 Product Portfolio
                         14.1.4.3. SWOT Analysis 
                         14.1.4.4. Strategic Overview
                         14.1.4.5. Financial Overview
              14.1.5. Horizon Pharma plc.
                         14.1.5.1. Company Overview (HQ, Business Segments, Employee Strengths)
                         14.1.5.2 Product Portfolio
                         14.1.5.3. SWOT Analysis 
                         14.1.5.4. Strategic Overview
                         14.1.5.5. Financial Overview
              14.1.6. Teva Pharmaceutical Industries Ltd.
                         14.1.6.1. Company Overview (HQ, Business Segments, Employee Strengths)
                         14.1.6.2 Product Portfolio
                         14.1.6.3. SWOT Analysis 
                         14.1.6.4. Strategic Overview
                         14.1.6.5. Financial Overview
              14.1.7 Hikma Pharmaceuticals PLC
                         14.1.7.1. Company Overview (HQ, Business Segments, Employee Strengths)
                         14.1.7.2 Product Portfolio
                         14.1.7.3. SWOT Analysis 
                         14.1.7.4. Strategic Overview
                         14.1.7.5. Financial Overview
              14.1.8. Iroko Pharmaceuticals, LLC 
                         14.1.7.1. Company Overview (HQ, Business Segments, Employee Strengths)
                         14.1.7.2 Product Portfolio
                         14.1.7.3. SWOT Analysis 
                         14.1.7.4. Strategic Overview
              14.1.9. MERCK & CO., Inc.
                         14.1.9.1. Company Overview (HQ, Business Segments, Employee Strengths)
                         14.1.9.2 Product Portfolio
                         14.1.9.3. SWOT Analysis         
                         14.1.9.4. Strategic Overview
                         14.1.9.5. Financial Overview

Choose License Type

Checkout Inquiry Sample